64309-39-3

Usage

Common usage

Research chemical

Known for

Potential pharmacological properties

Affinity

Dopamine receptors

Potential use

Treatment of neurological and psychiatric disorders (e.g. Parkinson's disease, schizophrenia)

Investigated for

Neuroprotective agent, modulation of neurotransmitter signaling in the brain

Promise

Wide range of potential applications in pharmacology and neurology

InChI:InChI=1/C16H25NO2/c1-3-9-17(10-4-2)13-6-7-14-12(11-13)5-8-15(18)16(14)19/h5,8,13,18-19H,3-4,6-7,9-11H2,1-2H3

Upstream product

• 55218-06-9 1,2,6-trimethoxynaphthalene 
• 52644-01-6 5,6-dimethoxy-2-tetralone 
• 58352-86-6 (+/-)-5,6-dimethoxy-2-(N,N-di-n-propylamino)tetralin 

Relevant academic research and scientific papers

Synthesis and pharmacology of some 2 aminotetralins. Dopamine receptor agonists

A series of 2 amino 1,2,3,4 tetrahydronaphthalene compounds bearing substituents on the nitrogen and in the aromatic ring was synthesized from β tetralone intermediates. Compounds were screened in vivo for dopaminergic activity using tests in which apomorphine was especially active. It was found that apparent dopaminergic activity is inherent in 2 dialkylaminotetralins, the dipropylamine substitution being the most consistently productive amine group studied. Activity was greatly enhanced by proper substitution in the aromatic ring. The 5,6 dihydroxy group was the best potentiating group found. These data support the idea that the extended conformation for the phenylethylamine moiety of apomorphine and dopamine is favorable for dopaminergic agonist activity. They also suggest that an unetherified catechol group may not be essential for such activity.